Nasdaq

Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS) | Nasdaq

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...
Nasdaq

Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time

– ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – PNH is a blood disorder characterized by complement-mediated ...
AOL

Alexion's Soliris® (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS

First and Only Approved Treatment in Japan for Patients Suffering from aHUS, a Chronic and Life-Threatening Ultra-Rare Disease aHUS is a life-threatening and ultra-rare chronic genetic disease that ...
FierceBiotech

Alexion’s Soliris follow-up clears trial in aHUS, its second rare disease

Alexion head of R&D John Orloff, M.D. (Alexion) () Smarting from a patent defeat for cash cow Soliris in Europe, Alexion has dulled the pain with a phase 3 readout that sets up new filings for ...
BioWorld

Alexion Gets FDA Nod, CHMP Thumbs-up for Soliris in AHUS

Only hours after announcing a positive recommendation in Europe for terminal complement inhibitor Soliris (eculizumab) in atypical hemolytic uremic syndrome (aHUS), Alexion Pharmaceuticals Inc. won ...